Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA14 | Q9ULX7 | 3/20 | 0.41 |
| ▸ | TSHR | P16473 | 4/20 | 0.39 |
| ▸ | ZDHHC7 | Q9NXF8 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.34 |
| ▸ | CA12 | O43570 | 2/20 | 0.34 |
| ▸ | CA1 | P00915 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 2/20 | 0.33 |
| ▸ | BIRC2 | Q13490 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
| ▸ | FURIN | P09958 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2256554 | 1.00 | CA14 (0.41) | CA14TSHRZDHHC7SMN1; SMN2CA12 | |
| SCHEMBL2259944 | 0.85 | METAP2 (0.38) | TSHRZDHHC7SMN1; SMN2KMT2A | |
| SCHEMBL2256244 | 0.85 | LMNA (0.35) | TSHR | |
| SCHEMBL2256242 | 0.85 | LMNA (0.35) | TSHR | |
| SCHEMBL2259941 | 0.85 | METAP2 (0.38) | TSHRZDHHC7SMN1; SMN2KMT2A | |
| SCHEMBL2259067 | 0.82 | CA12 (0.37) | CA14CA12CA1CA2MEN1 | |
| SCHEMBL2259068 | 0.82 | CA12 (0.37) | CA14CA12CA1CA2MEN1 | |
| SCHEMBL6850000 | 0.82 | CA1 (0.47) | CA14TSHRZDHHC7CA12CA1 | |
| SCHEMBL5191381 | 0.82 | CA1 (0.47) | CA14TSHRZDHHC7CA12CA1 | |
| Hydrochloric Acid SCHEMBL4084373 | 0.80 | CA1 (0.46) | CA14TSHRZDHHC7CA12CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8242303-B2 | Method of producing optically active N-(halopropyl) amino acid derivative | NAGASE & CO., LTD. (JP) | 2012-08-14 | — | — | US | claimed |
| EP-2192110-B1 | METHOD OF PRODUCING OPTICALLY ACTIVE N-(HALOPROPYL)AMINO ACID DERIVATIVE | NAGASE & CO LTD (JP) | 2016-05-04 | — | — | EP | disclosed |
| CN-101778815-B | Method of producing optically active n-(halopropyl)amino acid derivative | NAGASE & CO LTD | 2013-05-01 | — | — | CN | disclosed |
| US-8242303-B2 | Method of producing optically active N-(halopropyl) amino acid derivative | NAGASE & CO., LTD. (JP) | 2012-08-14 | — | — | US | disclosed |
| US-20110190527-A1 | METHOD OF PRODUCING OPTICALLY ACTIVE N-(HALOPROPYL) AMINO ACID DERIVATIVE | NAGASE & CO., LTD. (JP) | 2011-08-04 | — | — | US | disclosed |
| CN-101778815-A | Method of producing optically active n-(halopropyl)amino acid derivative | NAGASE & CO LTD | 2010-07-14 | — | — | CN | disclosed |
| EP-2192110-A1 | METHOD OF PRODUCING OPTICALLY ACTIVE N-(HALOPROPYL)AMINO ACID DERIVATIVE | Nagase & Co., Ltd. (JP) | 2010-06-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110190527-A1 | METHOD OF PRODUCING OPTICALLY ACTIVE N-(HALOPROPYL) AMINO ACID DERIVATIVE | NPPA, NPEPPS, ALAD | CA14 1026/4885TSHR 1997/4885ZDHHC7 403/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.